LETTER TO THE EDITOR
Serum CRP in Durvalumab-Tremelimumab Treated HCC: Expanding the Inflammatory Narrative
First published: 24 July 2025
Funding: This work was supported by State Administration of Traditional Chinese Medicine Science and Technology Department-Zhejiang Provincial Administration of Traditional Chinese Medicine Co-construction of Key Laboratory of Research on Prevention and Treatment for depression syndrome [No. GZY-ZJ-SY-2402]; Zhejiang Province 551 Health Talent Training Project (Zhejiang Provincial Health Commission Office [2021] No. 40).
Yuan Lei and Hailiang Xie contributed equally to the work.
No abstract is available for this article.
Open Research
Data Availability Statement
The authors have nothing to report.
